Journal
PHARMACOGENOMICS
Volume 14, Issue 3, Pages 315-324Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs.12.213
Keywords
anticancer agents; drug label; pharmacogenetics; pharmacogenomics
Categories
Funding
- NIH/NIGMS [K08GM089941]
- NIH/NCI [R21 CA139278]
- NIH/NIGMS Pharmacogenomics of Anticancer Agents grant [U01GM61393]
- University of Chicago Breast Cancer SPORE Career Development Award
- University of Chicago Cancer Center [P30 CA14599]
- National Center for Advancing Translational Sciences of the NIH [UL1RR024999]
Ask authors/readers for more resources
In the past decade, advances in pharmacogenetics and pharmacogenomics (PGx) have gradually unveiled the genetic basis of interindividual differences in drug responses. A large portion of these advances have been made in the field of anticancer therapy. Currently, the US FDA has updated the package inserts of approximately 30 anticancer agents to include PGx information. Given the complexity of this genetic information (e.g., tumor mutation and gene overexpression, chromosomal translocation and germline variations), as well as the variable level of scientific evidence, the FDA recommendation and potential action needed varies among drugs. In this review, we have highlighted some of these PGx discoveries for their scientific values and utility in improving therapeutic efficacy and reducing side effects. Furthermore, examples are also provided for the role of PGx in new anticancer drug development by revealing novel druggable targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available